WO2026110060 - TREATMENT OF MYASTHENIA GRAVIS USING A POPULATION OF CD19 CAR-EXPRESSING CELLS
National phase entry is expected:
Publication Number
WO/2026/110060
Publication Date
28.05.2026
International Application No.
PCT/IB2025/061872
International Filing Date
19.11.2025
Title **
[English]
TREATMENT OF MYASTHENIA GRAVIS USING A POPULATION OF CD19 CAR-EXPRESSING CELLS
[French]
TRAITEMENT DE LA MYASTHÉNIE GRAVE À L'AIDE D'UNE POPULATION DE CELLULES EXPRIMANT UN CAR CD19
Applicants **
NOVARTIS AG
Inventors
PEARSON, David Scott
ADIWIJAYA, Bambang Senoaji
STANGEL, Martin
Priority Data
63/723,285
21.11.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4055 | |
| EPO | Filing, Examination, Granting | 54182 | |
| Japan | Filing, Examination, Granting | 3884 | |
| South Korea | Filing, Examination, Granting | 5593 | |
| USA | Filing, Examination, Granting | 19740 |
Total:
87,454
Contact Us
Abstract[English]
The invention provides methods of using a population of CD19 CAR-expressing cells (for example, rapcabtagene autoleucel) for treating myasthenia gravis. Also disclosed are methods of making a population of CD19 CAR-expressing cells.[French]
L'invention concerne des méthodes d'utilisation d'une population de cellules exprimant un CAR CD19 (par exemple, le rapcabtagène autoleucel) pour le traitement de la myasthénie grave. Sont également divulguées des méthodes de fabrication d'une population de cellules exprimant un CAR CD19.